Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

被引：23

作者：

Zhou, Yuyong ^{[1
,2
]}

Gammeltoft, Karen A. ^{[1
,2
]}

Galli, Andrea ^{[1
,2
]}

Offersgaard, Anna ^{[1
,2
]}

Fahnoe, Ulrik ^{[1
,2
]}

Ramirez, Santseharay ^{[1
,2
]}

Bukh, Jens ^{[1
,2
]}

Gottwein, Judith M. ^{[1
,2
]}

机构：

[1] Copenhagen Univ Hosp Hvidovre, Dept Infect Dis, Copenhagen Hepatitis C Program CO HEP, Kettegard 30, DK-2650 Hvidovre, Denmark

[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen Hepatitis C Program CO HEP, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark

来源：

VIRUSES-BASEL | 2021年 / 13卷 / 10期

关键词：

SARS-CoV-2; COVID-19; drug repurposing; ion-channel inhibitor; antiviral; hepatitis C virus p7 inhibitor; adamantane; remdesivir; combination treatment; barrier to escape; SARS CORONAVIRUS; VIRUS;

D O I：

10.3390/v13102082

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 mu M, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.</p>

引用

页数：11

共 32 条

[1] Amantadine and rimantadine for influenza A in children and the elderly [J].